|
Feb 8
|
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
|
|
Feb 8
|
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
|
Feb 6
|
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
|
|
Dec 29
|
Tenax Therapeutics Announces Reverse Stock Split
|